Skip to main content
Top
Published in: AIDS and Behavior 12/2020

01-12-2020 | Human Immunodeficiency Virus | Original Paper

Antiretroviral Adherence, Drug Resistance, and the Impact of Social Determinants of Health in HIV-1 Patients in the US

Authors: C. Benson, X. Wang, K. J. Dunn, N. Li, L. Mesana, J. Lai, E. Y. Wong, W. Chow, H. Hardy, J. Song, K. Brown

Published in: AIDS and Behavior | Issue 12/2020

Login to get access

Abstract

Adherence to antiretroviral therapy (ART) is critical to achieving viral suppression. However, social determinants of health (SDoH) can undermine patient adherence to ART, resulting in drug resistance that compromises future treatment options. We assessed ART adherence and HIV-1 drug resistance at the national and state levels in the US and investigated their associations with SDoH and other HIV-related outcomes. Data were obtained from Symphony Health’s Integrated Dataverse (IDV), Monogram/LabCorp Database, as well as national and publicly available databases, including Centers for Disease Control and Prevention (CDC), American Community Survey (ACS), and J. Kaiser Family Foundation (KFF). Inferential analyses were performed to investigate associations using patient-level data, and the results were reported by state and overall within the nation. Correlations between continuous variables were estimated by the Spearman’s test, and that between continuous variable and categorical variable were estimated using one-way analysis of variance (ANOVA). State-level rates of poor adherence and resistance ranged from 26 to 55% and 20 to 54%, respectively. Female gender, non-white race, low education, poverty, and unemployment were associated with poor adherence; female gender was associated with drug resistance. Both adherence and resistance were correlated to HIV prevalence rates. Our findings suggest that US patients living with HIV face great challenges associated with poor ART adherence and HIV-1 drug resistance.
Appendix
Available only for authorised users
Literature
1.
go back to reference CDC. Today’s HIV/AIDS epidemic. CDC fact sheet (2016). CDC. Today’s HIV/AIDS epidemic. CDC fact sheet (2016).
2.
go back to reference Gunthard HF, Saag MS, Benson CA, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the international antiviral society-USA panel. JAMA. 2016;316(2):191–21010.CrossRef Gunthard HF, Saag MS, Benson CA, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the international antiviral society-USA panel. JAMA. 2016;316(2):191–21010.CrossRef
3.
go back to reference SSG Insight Start Study Group, Lundgren JD, Babiker AG, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373(9):795–807.CrossRef SSG Insight Start Study Group, Lundgren JD, Babiker AG, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373(9):795–807.CrossRef
4.
go back to reference Danel C, Moh R, Gabillard D, et al. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. The New England Journal of Medicine. 2015;373(9):808–22.CrossRef Danel C, Moh R, Gabillard D, et al. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. The New England Journal of Medicine. 2015;373(9):808–22.CrossRef
6.
go back to reference Ritchwood TD, Bishu KG, Egede LE. Trends in healthcare expenditure among people living with HIV/AIDS in the United States: evidence from 10 years of nationally representative data. Int J Equity Health. 2017;16(1):188–188.CrossRef Ritchwood TD, Bishu KG, Egede LE. Trends in healthcare expenditure among people living with HIV/AIDS in the United States: evidence from 10 years of nationally representative data. Int J Equity Health. 2017;16(1):188–188.CrossRef
10.
go back to reference Onoya D, Nattey C, Budgell E, et al. Predicting the need for third-line antiretroviral therapy by identifying patients at high risk for failing second-line antiretroviral therapy in South Africa. AIDS Patient Care STDs. 2017;31(5):205–12.CrossRef Onoya D, Nattey C, Budgell E, et al. Predicting the need for third-line antiretroviral therapy by identifying patients at high risk for failing second-line antiretroviral therapy in South Africa. AIDS Patient Care STDs. 2017;31(5):205–12.CrossRef
11.
go back to reference Nachega JB, Marconi VC, van Zyl GU, et al. HIV treatment adherence, drug resistance, virologic failure: evolving concepts. Infect Disord Drug Targets. 2011;11(2):167–74.CrossRef Nachega JB, Marconi VC, van Zyl GU, et al. HIV treatment adherence, drug resistance, virologic failure: evolving concepts. Infect Disord Drug Targets. 2011;11(2):167–74.CrossRef
12.
go back to reference Pennings PS. HIV drug resistance: problems and perspectives. Infect Dis Rep. 2013;5(Suppl 1):e5.CrossRef Pennings PS. HIV drug resistance: problems and perspectives. Infect Dis Rep. 2013;5(Suppl 1):e5.CrossRef
13.
go back to reference Rudy BJ, Murphy DA, Harris DR, Muenz L, Ellen J, Hivai ATN. Patient-related risks for nonadherence to antiretroviral therapy among HIV-infected youth in the United States: a study of prevalence and interactions. AIDS Patient Care STDS. 2009;23(3):185–94.CrossRef Rudy BJ, Murphy DA, Harris DR, Muenz L, Ellen J, Hivai ATN. Patient-related risks for nonadherence to antiretroviral therapy among HIV-infected youth in the United States: a study of prevalence and interactions. AIDS Patient Care STDS. 2009;23(3):185–94.CrossRef
14.
go back to reference Kleeberger CA, Phair JP, Strathdee SA, Detels R, Kingsley L, Jacobson LP. Determinants of heterogeneous adherence to HIV-antiretroviral therapies in the Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr. 2001;26(1):82–92.CrossRef Kleeberger CA, Phair JP, Strathdee SA, Detels R, Kingsley L, Jacobson LP. Determinants of heterogeneous adherence to HIV-antiretroviral therapies in the Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr. 2001;26(1):82–92.CrossRef
15.
go back to reference Do HM, Dunne MP, Kato M, Pham CV, Nguyen KV. Factors associated with suboptimal adherence to antiretroviral therapy in Viet Nam: a cross-sectional study using audio computer-assisted self-interview (ACASI). BMC Infect Dis. 2013;13:154.CrossRef Do HM, Dunne MP, Kato M, Pham CV, Nguyen KV. Factors associated with suboptimal adherence to antiretroviral therapy in Viet Nam: a cross-sectional study using audio computer-assisted self-interview (ACASI). BMC Infect Dis. 2013;13:154.CrossRef
16.
go back to reference Poles G, Li M, Siril H, et al. Factors associated with different patterns of nonadherence to HIV care in Dar es Salaam, Tanzania. J Int Assoc Provid AIDS Care. 2014;13(1):78–84.CrossRef Poles G, Li M, Siril H, et al. Factors associated with different patterns of nonadherence to HIV care in Dar es Salaam, Tanzania. J Int Assoc Provid AIDS Care. 2014;13(1):78–84.CrossRef
17.
go back to reference Beer L, Skarbinski J. Adherence to antiretroviral therapy among HIV-infected adults in the United States. AIDS Educ Prev. 2014;26(6):521–37.CrossRef Beer L, Skarbinski J. Adherence to antiretroviral therapy among HIV-infected adults in the United States. AIDS Educ Prev. 2014;26(6):521–37.CrossRef
18.
go back to reference EACS. European AIDS Clinical Society Guidelines 2017, 2017. EACS. European AIDS Clinical Society Guidelines 2017, 2017.
19.
go back to reference Iacob SA, Iacob DG, Jugulete G. Improving the adherence to antiretroviral therapy, a difficult but essential task for a successful HIV treatment-clinical points of view and practical considerations. Front Pharmacol. 2017;8:831.CrossRef Iacob SA, Iacob DG, Jugulete G. Improving the adherence to antiretroviral therapy, a difficult but essential task for a successful HIV treatment-clinical points of view and practical considerations. Front Pharmacol. 2017;8:831.CrossRef
20.
go back to reference Lafeuille MH, Woodruff K, Dunn K, et al. Adherence to antiretrovirals (ARVs) in medicaid-insured patients living with human immunodeficiency virus (HIV). Presented at the Academy of Managed Care Pharmacy (AMCP) managed care & specialty pharmacy annual meeting, March 27–30, 2017, Denver, Colorado. Lafeuille MH, Woodruff K, Dunn K, et al. Adherence to antiretrovirals (ARVs) in medicaid-insured patients living with human immunodeficiency virus (HIV). Presented at the Academy of Managed Care Pharmacy (AMCP) managed care & specialty pharmacy annual meeting, March 27–30, 2017, Denver, Colorado.
21.
go back to reference Forlenza J, Brown K, Shprecher A, et al. An evaluation of patient characteristics, duration on antiretrovirals (ARVs) and adherence in a large, insured United States population receiving HIV treatment between 2010 and 2014. Open Forum Infect Dis. 2015;2(Suppl 1):416.CrossRef Forlenza J, Brown K, Shprecher A, et al. An evaluation of patient characteristics, duration on antiretrovirals (ARVs) and adherence in a large, insured United States population receiving HIV treatment between 2010 and 2014. Open Forum Infect Dis. 2015;2(Suppl 1):416.CrossRef
22.
go back to reference McClung RP, Saduvala N, Oster AM, Heneine W, Johnson JA, Hernandez AL. Integrase and other transmitted HIV drug resistance: 23 US jurisdictions, 2013–2016, March 4–7, 2019, Seattle, Washington. McClung RP, Saduvala N, Oster AM, Heneine W, Johnson JA, Hernandez AL. Integrase and other transmitted HIV drug resistance: 23 US jurisdictions, 2013–2016, March 4–7, 2019, Seattle, Washington.
23.
go back to reference Kim J, Lee E, Park BJ, Bang JH, Lee JY. Adherence to antiretroviral therapy and factors affecting low medication adherence among incident HIV-infected individuals during 2009–2016: a nationwide study. Sci Rep. 2018;8(1):3133.CrossRef Kim J, Lee E, Park BJ, Bang JH, Lee JY. Adherence to antiretroviral therapy and factors affecting low medication adherence among incident HIV-infected individuals during 2009–2016: a nationwide study. Sci Rep. 2018;8(1):3133.CrossRef
24.
go back to reference Rachlis B, Burchell AN, Gardner S, et al. Social determinants of health and retention in HIV care in a clinical cohort in Ontario, Canada. AIDS Care. 2017;29(7):828–37.CrossRef Rachlis B, Burchell AN, Gardner S, et al. Social determinants of health and retention in HIV care in a clinical cohort in Ontario, Canada. AIDS Care. 2017;29(7):828–37.CrossRef
25.
go back to reference Morowatisharifabad MA, Movahed E, Farokhzadian J, et al. Antiretroviral therapy adherence and its determinant factors among people living with HIV/AIDS: a case study in Iran. BMC Res Notes. 2019;12(1):162.CrossRef Morowatisharifabad MA, Movahed E, Farokhzadian J, et al. Antiretroviral therapy adherence and its determinant factors among people living with HIV/AIDS: a case study in Iran. BMC Res Notes. 2019;12(1):162.CrossRef
26.
go back to reference Bradley ELP, Frazier EL, Carree T, Hubbard McCree D, Sutton MY. Psychological and social determinants of health, antiretroviral therapy (ART) adherence, and viral suppression among HIV-positive black women in care. AIDS Care. 2019;31(8):932–41.CrossRef Bradley ELP, Frazier EL, Carree T, Hubbard McCree D, Sutton MY. Psychological and social determinants of health, antiretroviral therapy (ART) adherence, and viral suppression among HIV-positive black women in care. AIDS Care. 2019;31(8):932–41.CrossRef
Metadata
Title
Antiretroviral Adherence, Drug Resistance, and the Impact of Social Determinants of Health in HIV-1 Patients in the US
Authors
C. Benson
X. Wang
K. J. Dunn
N. Li
L. Mesana
J. Lai
E. Y. Wong
W. Chow
H. Hardy
J. Song
K. Brown
Publication date
01-12-2020
Publisher
Springer US
Published in
AIDS and Behavior / Issue 12/2020
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-020-02937-8

Other articles of this Issue 12/2020

AIDS and Behavior 12/2020 Go to the issue